1. Clinical Overview
This is a fixed-dose combination of a uroprotective agent (Mesna) and an alkylating antineoplastic agent (Ifosfamide). Mesna is specifically included to prevent the dose-limiting urotoxic side effects, particularly hemorrhagic cystitis, caused by Ifosfamide's toxic metabolites (acrolein). Ifosfamide is a prodrug requiring hepatic activation. The combination is a cornerstone of several high-intensity chemotherapy regimens used primarily for solid tumors and sarcomas in the Indian oncology setting.
| Onset | Duration | Bioavailability |
|---|---|---|
| Ifosfamide: Hepatic activation begins within 1-2 hours. Mesna: Rapid, within 1 hour of IV administration for uroprotection. | Ifosfamide: Cytotoxic effects are cell-cycle non-specific but depend on exposure to active metabolites. Mesna: Uroprotective effect lasts approximately 4-8 hours per dose, necessitating multiple doses. | Ifosfamide: Oral bioavailability is highly variable and poor (~96% for IV route). Mesna: Oral bioavailability is approximately 50-75%; IV route is preferred in combination with IV Ifosfamide for reliable protection. |
2. Mechanism of Action
Ifosfamide is a prodrug activated by hepatic microsomal enzymes to 4-hydroxyifosfamide, which spontaneously forms the active alkylating agent, isophosphoramide mustard, and the toxic byproduct, acrolein. Isophosphoramide mustard cross-links DNA strands, inhibiting DNA replication and transcription, leading to cell death. Acrolein causes direct chemical irritation and damage to the urothelium, leading to hemorrhagic cystitis. Mesna provides specific, local detoxification in the urinary tract. It is rapidly oxidized to dimesna in plasma, which is filtered by the glomerulus. In the renal tubules, dimesna is reduced back to free mesna, which binds to and inactivates acrolein, forming a stable, non-toxic thioether compound that is excreted.
3. Indications & Uses
- Germ cell testicular cancer (salvage therapy)
- Soft tissue sarcoma (e.g., Ewing's sarcoma, osteosarcoma)
- Non-Hodgkin's lymphoma (relapsed/refractory)
- Small cell lung cancer
4. Dosage & Administration
Adult Dosage: Ifosfamide: 1.2 to 2.0 g/m²/day IV over 30-120 minutes for 3-5 consecutive days every 3-4 weeks. High-dose regimens use up to 5 g/m²/day. Mesna: Dose is a percentage of the ifosfamide dose. Standard: 60% of ifosfamide dose given as IV bolus at 0 hours (with ifosfamide), 4 hours, and 8 hours post-ifosfamide. Alternative: 20% of ifosfamide dose given IV concurrently, followed by continuous IV infusion of 40% of ifosfamide dose over 12-24 hours.
Administration: Administer in a hospital setting under supervision of an oncologist. Pre-hydrate with 1-2L of IV fluids (e.g., Dextrose 5% or Normal Saline). Ifosfamide is given as an IV infusion over 30 minutes to several hours. Mesna is given as IV bolus injections or infusion as per schedule. Maintain high urine output (>100 mL/hr) during and for at least 24 hours after therapy. Monitor urine for blood (dipstick) each day.
5. Side Effects
Common side effects may include:
- Nausea and vomiting (requires potent antiemetics)
- Alopecia (reversible)
- Myelosuppression (Leukopenia, Neutropenia, Thrombocytopenia)
- Hematuria (microscopic or gross, despite mesna)
- Fatigue
- Anorexia
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Allopurinol | May increase risk of ifosfamide-induced neurotoxicity. | Moderate |
| CYP3A4 Inducers (e.g., Phenobarbital, Phenytoin, Rifampicin, Carbamazepine) | Increase metabolism of ifosfamide to active/toxic metabolites, potentially increasing efficacy and toxicity (myelosuppression, neurotoxicity). | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | Decrease activation of ifosfamide, potentially reducing efficacy. | Major |
| Warfarin | Ifosfamide may enhance anticoagulant effect; monitor INR closely. | Moderate |
| Nephrotoxic drugs (e.g., Aminoglycosides, Amphotericin B, Cisplatin) | Additive risk of renal impairment. | Major |
| Myelosuppressive drugs (other chemotherapy, clozapine) | Additive bone marrow suppression. | Major |
| CNS Depressants (e.g., Benzodiazepines, Opioids) | May exacerbate ifosfamide-induced neurotoxicity (sedation, confusion). | Moderate |
| Live Vaccines | Risk of disseminated infection due to immunosuppression. | Major |
7. Patient Counselling
- DO drink at least 2-3 liters of fluids (water, juices) daily for 3 days after each treatment to flush your bladder.
- DO report immediately any blood in urine, pain or burning during urination, or decreased urine output.
- DO use effective contraception (both males and females) during and for at least 6 months after therapy.
- DO keep all follow-up appointments for blood tests (CBC, renal function).
- DONT miss any scheduled doses of mesna; it is critical for bladder protection.
- DONT drive, operate machinery, or make important decisions for 2-3 days after treatment due to risk of confusion/drowsiness.
- DONT take any other medicines (including OTC, herbal) without consulting your oncologist.
- DONT come in close contact with people who have infections (colds, flu).
8. Toxicology & Storage
Overdose: Manifestations of severe toxicity: Exaggerated myelosuppression (pancytopenia, infection, hemorrhage), severe hemorrhagic cystitis with massive hematuria, severe neurotoxicity (coma, seizures), acute renal failure, cardiotoxicity, and hepatotoxicity.
Storage: Store vials/powder at controlled room temperature (15°C to 30°C). Protect from light and moisture. Reconstituted solutions: Ifosfamide is stable for varying periods depending on diluent (e.g., 7 days at 5°C in Water for Injection). Mesna solution is stable for 24 hours at room temperature. Follow manufacturer's instructions for specific brands. Do not freeze. Keep out of reach of children. Dispose of unused medicine and contaminated materials as per hospital biohazard protocols.